Pembrolizumab Alone and In Combination With Acalabrutinib (ACP-196) in Subjects With Advanced Non-small Cell Lung Cancer

NCT02448303 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

74

Enrollment

INDUSTRY

Sponsor class

Conditions

Carcinoma, Non-Small-Cell Lung

Interventions

DRUG: Pembrolizumab
DRUG: Acalabrutinib

Sponsor

Acerta Pharma BV

Collaborators

[object Object]